Management of Aggressive Lymphoma in Very Elderly Patients

Overview

Journal Hematol Oncol

Specialties Hematology
Oncology

Date 2017 Jun 8

PMID 28591412

Citations 6

Authors

Catherine Thieblemont

Sophie Bernard

Thierry Molina

Affiliations

Soon will be listed here.

Citing Articles

A 95-year-old patient suffered high-grade B-cell lymphoma combined hairy cell leukemia.

Wang L, Wang J, Li M, Tian L Leuk Res Rep. 2024; 21:100457.

PMID: 39035748 PMC: 11258385. DOI: 10.1016/j.lrr.2024.100457.

Fast Track Management of Primary Thyroid Lymphoma in the Very Elderly Patient.

Marcy P, Bauduer F, Thariat J, Gisserot O, Ghanassia E, Chetaille B Curr Oncol. 2023; 30(6):5816-5827.

PMID: 37366918 PMC: 10297318. DOI: 10.3390/curroncol30060435.

Is endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) reliable and safe procedure in geriatric patients?.

Gurun Kaya A, Ciledag A, Erol S, Oz M, Dogan Mulazimoglu D, Isik O Aging Clin Exp Res. 2021; 34(4):913-925.

PMID: 34731449 DOI: 10.1007/s40520-021-02012-9.

Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients.

Mead M, Cederleuf H, Bjorklund M, Wang X, Relander T, Jerkeman M Blood Adv. 2021; 6(7):2120-2128.

PMID: 34570186 PMC: 9006283. DOI: 10.1182/bloodadvances.2021004269.

Primary non-Hodgkin diffuse large B-cell lymphoma of the lacrimal sac: a rare case of aggressive tumor and literature review.

Malzone M, Di Meglio M, Furgiuele D, Galantuomo N, Alfano S, Mossetti G Med Pharm Rep. 2021; 94(3):377-381.

PMID: 34430862 PMC: 8357362. DOI: 10.15386/mpr-1926.

References

Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F . The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011; 96(12):1888-90. PMC: 3232277. DOI: 10.3324/haematol.2011.050617. View

Klapper W, Kreuz M, Kohler C, Burkhardt B, Szczepanowski M, Salaverria I . Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012; 119(8):1882-7. DOI: 10.1182/blood-2011-10-388470. View

Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer M . Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2009; 21(7):1492-1499. DOI: 10.1093/annonc/mdp544. View

Pfreundschuh M . How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010; 116(24):5103-10. DOI: 10.1182/blood-2010-07-259333. View

Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile J, Castaigne S . Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011; 12(5):460-8. DOI: 10.1016/S1470-2045(11)70069-9. View

Balducci L, Repetto L . Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer. 2003; 100(1):6-11. DOI: 10.1002/cncr.11861. View

Thieblemont C, Bernard S, Molina T . Management of aggressive lymphoma in very elderly patients. Hematol Oncol. 2017; 35 Suppl 1:49-53. PMC: 5873382. DOI: 10.1002/hon.2413. View

Peyrade F, Bologna S, Delwail V, Emile J, Pascal L, Ferme C . Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017; 4(1):e46-e55. DOI: 10.1016/S2352-3026(16)30171-5. View

Fridrik M, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A . Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse.... Eur J Cancer. 2016; 58:112-21. DOI: 10.1016/j.ejca.2016.02.004. View

10.

Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C . Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol. 2007; 19(4):774-9. DOI: 10.1093/annonc/mdm563. View

11.

Dubois S, Viailly P, Mareschal S, Bohers E, Bertrand P, Ruminy P . Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. Clin Cancer Res. 2016; 22(12):2919-28. DOI: 10.1158/1078-0432.CCR-15-2305. View

12.

Cabannes-Hamy A, Peyrade F, Jardin F, Emile J, Delwail V, Mounier N . Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. Cancer Med. 2018; 7(3):539-548. PMC: 5852369. DOI: 10.1002/cam4.1139. View

13.

Trebouet A, Marchand T, Lemal R, Gyan E, Broussais-Guillaumot F, Guillermin Y . Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann Oncol. 2013; 24(10):2612-2618. DOI: 10.1093/annonc/mdt282. View

14.

. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1997; 8(10):973-8. View

15.

Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D . MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015; 126(22):2466-74. DOI: 10.1182/blood-2015-05-647602. View

16.

Soubeyran P, Fonck M, Blanc-Bisson C, Blanc J, Ceccaldi J, Mertens C . Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012; 30(15):1829-34. DOI: 10.1200/JCO.2011.35.7442. View